Offering end-to-end chronic wound care solutions, which are personalized and affordable
Healiva is a patient-centric Biotech commercializing a portfolio of innovative, personalized and affordable therapies for chronic and acute wounds and targeting key pain points in the patient care pathway.
Epidex®
Epidermal cell graft
Personalized treatment for the most severe chronic wounds
AQUAtyrp
Healiva 003
Enzymatic debriding agent
Painless, easy-to-use and more effective for wound cleaning and preparation.
Healiva 002
Allogenic cell spray
Growth factor stimulation with ability to scale to large number of patients
Healiva 004
Blood Patch
Autologous patch prepared at Point of Care by healthcare professional.
No satisfactory therapy for hard-to-heal wounds currently exists…
There are 156m patients are estimated in the world to suffer from chronic wounds :
- 2-3% of the elderly have painful Venous/Arterial Leg Ulcers
- 25% of diabetics have disabling diabetic foot ulcers
- 60% of chronic wounds remain unhealed
… and the treatment is very costly
​
- Repeated surgical procedures
- Requirement of medical expertise
- Frequency of dressing changes
- Lengthy hospital stays
This is inefficient and is a financial burden on patients and society
Product Pipeline
2024
Cell Therapy -
Epidex / Healiva 001
2025
Wound Debriber -
AQUAtyrp / Healiva 003
2026
Medical Device –
Blood patch / Healiva 004
2027
Cell Therapy –
Allogenic cell therapy / Healiva 002
Member of :
